Lifeboat Foundation

Roboticists at the California Institute of Technology launched an initiative called RoAMS, which uses the latest research in robotic walking to create a new kind of medical exoskeleton. With the ability to move dynamically, using neurocontrol interfaces, these exoskeletons allow users to balance and walk without the crutches. Learn more in the latest IEEE Spectrum article! https://ieeexplore.ieee.org/document/8946313 #RoAMS #exoskeletons

Bipedal robots have long struggled to walk as humans do-balancing on two legs and moving with that almost-but-not-quite falling forward motion that most of us have mastered by the time we’re a year or two old. It’s taken decades of work, but robots are starting to get comfortable with walking, putting them in a position to help people in need.

He remarks that we are at Kittyhawk as far as life extension goes. Most folks, including the Wright brothers, did not see a widespread use for aircraft at the time. Today in life extension the scientists working on it really do know what they are chasing.

My mission is to drastically improve your life by helping you break bad habits, build and keep new healthy habits to make you the best version of yourself.

Continue reading “Dr. Michael Fossel, President of Telocyte” »

Tushna Commissariat reviews The Space Race: the Journey to the Moon and Beyond by Sarah Cruddas.

Vlog “Posthumans” — Episode 22
Dr. Francesca Ferrando (NYU) interviews Dr. Aubrey de Grey, (SENS Research Foundation). Recorded at Princeton University (US), November 2019. Video-grapher and video-producer: Julian Boilen.

More info: http://www.theposthuman.org/vlog-posthumans.html

Continue reading “Radical Life Extension in the Posthuman Era — Dr. Aubrey de Grey interviewed by Prof. Ferrando (NYU)” »

He made his whole apartment in VR! 🤯

Credit:: Greg Medison

In order to develop solar panels that generate electricity at night, you just need them to operate in the exact opposite way solar panels work during the day.

It’s a model the company believes makes sense because the right answer for getting regulatory approval and delivering service in the United States or the Philippines or Indonesia will vary, Steckel said. “We’re going to be doing business with partners around the world,” Steckel said. “Our style is not confrontational. We’re using a different model. It’s a big world.”

OneWeb plans to offer its first customer demonstrations by the end of 2020 and provide full commercial global services in 2021.

In the future of urban warfare, swarms of autonomous drones and ground vehicles will win battles before they even begin.

DARPA’s OFFensive Swarm-Enabled Tactics (OFFSET) program recently tested a swarm of 250 unmanned vehicles in a mock city at Camp Shelby Joint Forces Training Center in Mississippi.

We developed a Waon therapy (soothing warm therapy) and have previously reported that repeated Waon therapy improves hemodynamics, peripheral vascular function, arrhythmias, and clinical symptoms in patients with chronic heart failure (CHF). The aim of this study was to investigate the effect of Waon therapy on the prognosis of CHF patients.

We studied 129 patients with CHF in NYHA functional class III or IV who were admitted to our hospital between January 1999 and March 2001. In the Waon therapy group, 64 patients were treated with a far infrared-ray dry sauna at 60 °C for 15 min and then kept on bed rest with a blanket for 30 min. The patients were treated daily for 5 days during admission, and then at least twice a week after discharge. In the control group, 65 patients, matched for age, gender, and NYHA functional class, were treated with traditional CHF therapy. The follow-up time was scheduled for 5 years.

Recent, complete follow-up data on each patient were obtained. The overall survival rate was 84.5% (Kaplan–Meier estimate). Twelve patients died in the control group and 8 patients died in the Waon therapy group at 60 months of follow-up. Cardiac events due to heart failure or cardiac death occurred in 68.7% of the control group but only 31.3% of the Waon therapy group (P < 0.01) at 60 months of follow-up.